DOWNSIZED looks at EASD 2026 data on an amylin-based drug reaching 23% weight loss and how it might stack up against retatrutide.
Recap by typeshit. Full story at DOWNSIZED.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
Polish public radio covers a new weight-loss medication being talked about as a successor to Ozempic. Details are thin beyond the headline.
A clinician reminds patients on GLP-1 medications that their bodies are not flawed or broken. A short brand post with a body-positive message.
Loading…